Zykadia for Non-Small Cell Lung Cancer (Resubmission) – Details


( Last Updated : April 5, 2017)
Generic Name:
Ceritinib
Project Status:
Complete
Therapeutic Area:
metastatic non-small cell lung cancer
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Zykadia (Resubmission)
Project Line:
Reimbursement Review
Project Number:
PC0094-000
NOC Status at Filing:
Pre NOC
NOC Date:

Details


Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib
Date NOC Issued:
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.